Sam Altman-Backed Retro Biosciences Raising $1 Billion to Extend Human Lifespan
Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...
newsbytesapp.com2d
Sam Altman-backed start-up is raising $1B to extend human lifespan
OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...
STAT2d
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan
OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to ...
bovnews2d
Unity Biotechnology Inc (UBX) Stock: Analyzing Its Quiet Power
Unity Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 76.03%. The profit margin, also known as the revenue ratio or gross profit ratio ...
Guggenheim raises Immunovant stock target to $46, maintains Buy
Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
UBX stock touches 52-week high at $2.02 amid market optimism
Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...